Since G9a is overexpressed in many different types of cancers, and has been shown to be responsible for various aspects of tumorigenesis, including cellular differentiation, proliferation, and epithelial to mesenchymal, indicates that G9a could be a feasible target for cancer therapy. Here, EHMT2 is linked to cancer.